Complete genomics inc (GNOM)
CashFlow / Yearly
Dec'11Dec'10Dec'09
Net loss

-72,348

-57,687

-35,949

Depreciation and amortization

11,715

8,018

5,240

Amortization of debt issuance costs

-

410

259

Write-down of inventory

933

148

-

Issuance of common stock to founders

-

1,840

-

Change in fair value of warrant liability

-361

-7,211

1,088

Stock-based compensation

4,324

1,751

1,410

Noncash interest expense related to notes payable

670

1,485

2,113

Other

84

109

31

Accounts receivable

1,589

3,655

1,288

Inventory

1,074

3,774

354

Prepaid expenses

40

-4,055

4,688

Other current assets

263

-119

-110

Other assets

437

53

143

Accounts payable

1,226

481

1,078

Accrued liabilities

2,417

788

288

Deferred revenue

4,287

4,437

1,302

Deferred rent

-777

-701

5,017

Net cash used in operating activities

-50,511

-35,018

-26,662

Purchase of available-for-sale securities

52,653

-

-

Proceeds from maturities of available-for-sale securities

46,653

-

-

Purchase of property and equipment

20,395

18,802

9,654

Increase in restricted cash

500

-

-

Purchase of patent

250

-

-

Net cash used in investing activities

-27,145

-18,802

-9,654

Proceeds from promissory notes

-

22,243

14,725

Proceeds from notes payable

20,000

14,000

-

Repayment of notes payable

9,560

8,643

3,990

Proceeds from issuance of convertible preferred stock, net of issuance costs

-

39,402

27,156

Proceeds from issuance of common stock, net of costs

73,932

47,175

-

Proceeds from issuance of common stock under equity incentive plans

1,440

796

4

Net cash provided by financing activities

85,812

114,973

37,895

Net decrease in cash and cash equivalents

8,156

61,153

1,579

Cash paid for interest

2,191

1,198

1,068

Issuance of warrants for convertible preferred stock in connection with promissory notes

-

-

1,541

Issuance of warrants for common stock in connection with convertible preferred stock financings

-

2,020

1,999

Conversion of promissory notes and interest into convertible preferred stock

-

15,403

15,054

Acquisition of property and equipment under accounts payable

1,071

1,696

2,458

Issuance of warrants for common stock in connection with notes payable

987

5,671

-

Issuance of purchase rights for Series E convertible preferred stock

-

2,666

-

Reclassification of purchase right liability to preferred stock upon exercise

-

9,153

-

Conversion of preferred stock into common stock upon initial public offering

-

147,765

-

Deemed dividend related to the beneficial conversion feature of Series E convertible preferred stock

-

405

-